AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01440569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: 150 mg tablet administered orally with food once daily
Study NCT01440569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DRV
Description: 800 mg (2 x 400 mg tablets) administered orally with food once daily
Study NCT01440569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRTIs
Description: Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
Study NCT04209439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 30 ml %0.25 bupivacaine
Description: Ultrasound-guided erector spinae plane block
Study NCT04209439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen-trometamol
Description: 50 mg Dexketoprofen-trometamol intravenous
Study NCT04328610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LYMPHA(LYmphatic Microsurgical Preventive Healing Approach) technique
Description: Patients will receive a lymphatic-venous anastomosis at time of their required Axillary Dissection
Study NCT01120132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA high dose
Description: Solution of Cyclosporine (high dose) administered during 28 days
Study NCT01120132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA low dose
Description: Solution of Cyclosporine (low dose) administered during 28 days
Study NCT01120132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA
Description: Suspension of Prednisolone Acetate administered during 28 days
Study NCT01120132 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PA
Description: Suspension of Prednisolone Acetate administered during 28 days
Study NCT01120132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo solution administered during 28 days
Study NCT01120132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution administered during 28 days
Study NCT04002778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fine needle aspiration
Study NCT04002778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fine needle aspiration
Study NCT04002778 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rapid on-site evaluation
Study NCT01399476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Myotomy
Description: Patients will receive the surgical procedure described in the summary (POEM).
Study NCT01399476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Myotomy for treatment of achalasia
Description: Surgical procedure
Study NCT00840736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic adjustable gastric banding
Description: Laparoscopic adjustable gastric banding
Study NCT00840736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical banded gastroplasty
Description: vertical banded gastroplasty
Study NCT03988673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision aid with implicit values clarification method (booklet or website)
Description: The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a grid where statements about the subject will be presented (decision aid with implicit VCM).
Study NCT03988673 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Decision aid with explicit values clarification method (booklet or website)
Description: The intervention will be an informative evidence-based material in the format of a booklet or website concerning prostate cancer screening. The values clarification method will be a a grid where statements about the subject will be presented and men should indicate what statements they identify with (decision aid with explicit VCM).
Study NCT02379507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DEC033 Study Product
Description: Apply twice daily
Study NCT04647994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SARS-CoV-2 serology
Description: Serology test of SARS-CoV-2 for pregnant women
Study NCT03252366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GELFOAM
Description: * Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study NCT03252366 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: xenograft
Description: * Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.~* A diamond bur will be used to make a rectangular osteotomy.~* The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.~* Implant stability will be measured by osteal device~* implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.~* The flap will then be closed using interrupted 4/0 resorbable sutures.
Study NCT02357615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nifedipine CR tablets (Xin Ran)
Study NCT02357615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalat
Study NCT02163642 — intervention group
Intervention type: DEVICE
Intervention: Cyranose® 320
Description: Detection of patterns of specific Volatile Organic Compounds in exhaled air
Study NCT03296566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Liaison
Description: An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
Study NCT00526097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisacodyl 10 mg
Description: 2 x 5 mg bisacodyl once daily
Study NCT00526097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
Study NCT04591262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06826647-LR 600 mg PO
Description: 14C-PF-06826647-LR 600 mg with 300 nCi orally as extemp prep
Study NCT04591262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06826647 600 mg PO
Description: Unlabeled PF-06826647 600 mg
Study NCT04591262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-PF-06826647 100 ug IV
Description: 14C-PF-06826647 100 ug IV
Study NCT02627768 — intervention group
Intervention type: DRUG
Intervention: No Intervention
Description: Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
Study NCT03305887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRATAFIX™ Symmetric Knotless Tissue
Description: This devices will be used in deep and intermediate layers of barbed suture group.
Study NCT03305887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VICRYL® PLUS
Description: This devices will be used in deep and intermediate layers of conventional suture group.
Study NCT03305887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STRATAFIX Spiral sutures
Description: This devices will be used in intradermal layer of both barbed suture and conventional suture group.
Study NCT03305887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STRATAFIX Spiral sutures
Description: This devices will be used in intradermal layer of both barbed suture and conventional suture group.
Study NCT03305887 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DERMABOND™ Advance™ Skin Closure System
Description: This devices will be used in skin layer of both barbed suture and conventional suture group.
Study NCT03305887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DERMABOND™ Advance™ Skin Closure System
Description: This devices will be used in skin layer of both barbed suture and conventional suture group.
Study NCT02396446 — intervention group
Intervention type: OTHER
Intervention: Abdominal acoustic measurement
Description: Device meant to listen to the sounds of the gut to determine post op ileus.
Study NCT02718547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combigan
Description: Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
Study NCT00630552 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dummy of AMG 655.
Study NCT00630552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
Study NCT00630552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 655
Description: AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
Study NCT00721214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine
Description: The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
Study NCT03433183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib (AZD6244) is an oral selective inhibitor of the mitogen-activated protein kinase (MEK) 1/2 currently in development for adult malignancies, pediatric low-grade gliomas and NF1 plexiform neurofibromas. MEK is a critical kinase in the mitogen activated protein (MAP) kinase signal transduction pathway for many growth factor receptors that provide growth signals to cancer cells.
Study NCT03433183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus and inhibitor of mammalian Target of Rapamycin (mTOR) serine threonine kinase, which plays a critical role in regulating cellular energy sensing, growth and metabolism.
Study NCT02230293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidisciplinary assistance
Description: Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
Study NCT02230293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment and follow up
Description: Assistance was effected by physician and nurse and consisted about adapting to the drug
Study NCT00038155 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ambulation training
Description: Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
Study NCT03745378 — intervention group
Intervention type: OTHER
Intervention: JAK2V617F mutation
Description: JAK2 V617F is attached to the cytosolic juxtamembrane region of dimeric cytokine receptors, such as EpoR or MPL (TpoR); The JAK2V617F mutation results from a guanine to thymine change at nucleotide 1849 of the cDNA, in exon 14 of the gene. This valine is located at one of the predicted interfaces between JH1 and JH2 domains,
Study NCT03866980 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK105
Description: IV infusion
Study NCT03866980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: IV infusion
Study NCT03866980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: IV infusion
Study NCT03866980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: IV infusion
Study NCT03866980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pemetrexed
Description: IV infusion
Study NCT03866980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV infusion
Study NCT03866980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: PO
Study NCT01284309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral
Study NCT01284309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT02719262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: installing ventilation in the workplace
Description: Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
Study NCT01178307 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: 10 minutes to complete 3 questionnaires for development of MDASI-GIST
Study NCT01178307 — intervention group
Intervention type: BEHAVIORAL
Intervention: Interview
Description: Each interview will take approximately 30 minutes.
Study NCT01178307 — intervention group
Intervention type: BEHAVIORAL
Intervention: MDASI-GIST Questionnaire
Description: Every 4 weeks for one year
Study NCT03459859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Administered intravenous (IV) infusion over one hour on Days 1, 3 and 5 of each cycle, after administration of LDAC per protocol.
Study NCT03459859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Low dose Cytarabine (LDAC) administered subcutaneously (SC) daily for 10 days of every 28-day cycle.
Study NCT01808898 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anaesthetic
Description: On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
Study NCT01808898 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Local Anaesthetic
Description: On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
Study NCT02168231 — intervention group
Intervention type: PROCEDURE
Intervention: Complex abdominal wall repair Strattice
Description: Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
Study NCT02363998 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lofexidine
Description: All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
Study NCT03788122 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: In-depth interview
Description: The 'intervention' administered to this group of participants are two or three in-depth interviews (average 30-60 m minutes per interview) on their experiences, views, feelings and thoughts (perceptions) regarding acceptability of the fetal surgery.
Study NCT04959578 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human erythropoietin
Description: Dose, route and schedule was kept same as previous erythropoietin dose at randomization; adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
Study NCT04959578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin Alfa
Description: Dose conversion (100U erythropoietin = 0.42 mcg darbeopoetin). DA dose was kept once weekly (QW) if previously receiving rHuEpo ≥2 times a week, or Q2W if previously receiving rHuEpo \<2 times a week. Dose was adjusted as necessary (+/- 25% of the starting dose) to maintain Hb within 11 - 12 g/dL.
Study NCT03616860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound (FUS) BBB Disruption
Description: FUS BBB disruption involves the application of acoustic energy at low frequencies from over 1000 individual transducers into distinct body targets
Study NCT02162017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The lying flat (0°) head position for 24 hours
Description: The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
Study NCT02162017 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The sitting-up (≥30°) head position for 24 hours
Description: For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
Study NCT05444036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: compare caudal ketamine-bupivacaine against caudal bupivacaine-saline in paediatric Measuring pain in patients undergoing surgery below the umbilicus with regard to analgesic, anaesthetic, and sedative properties
Study NCT00175045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
Study NCT00175045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
Study NCT04308213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Marrow Cellution System
Description: The treatment will be carried out in the operating room under ordinary hospitalization and provides the intra-articular application of 9 ml of autologous bone marrow aspirate in the glenohumeral joint affected by arthrosis. To obtain the necessary amount, a bone marrow aspirate of about 12 ml will be taken from the iliac crest by means of the Marrow Cellution System, Geistlich Italia. This autologous bone marrow aspirate will be injected using the same syringe into the glenohumeral joint affected by arthrosis under amplioscopic control.
Study NCT01858051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study NCT01858051 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01395498 — intervention group
Intervention type: OTHER
Intervention: laboratory testing of PCP and CMV genetic material
Description: laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
Study NCT00392535 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: conventional radiotherapy 74 Gy delivered in 37 fractions
Study NCT00392535 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy 60 Gy in 20 fractions
Study NCT00392535 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: hypofractionated radiation therapy 57 Gy in 19 fractions
Study NCT03962764 — intervention group
Intervention type: BEHAVIORAL
Intervention: Responsible Fatherhood Program
Description: 24 hours of fatherhood curriculum, 6 hours of financial literacy, workforce development, and case management.
Study NCT01903083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
Study NCT01903083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Three doses of gemcitabine (1000 mg / m\^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
Study NCT01903083 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Patients will receive 3 doses of radiation (8-10 Gy per fraction).
Study NCT01903083 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy
Description: Surgical resection.